0000950170-24-076380.txt : 20240621
0000950170-24-076380.hdr.sgml : 20240621
20240621180015
ACCESSION NUMBER: 0000950170-24-076380
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240618
FILED AS OF DATE: 20240621
DATE AS OF CHANGE: 20240621
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: VAN NOSTRAND ROBERT L
CENTRAL INDEX KEY: 0001225198
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36274
FILM NUMBER: 241061589
MAIL ADDRESS:
STREET 1: C/O ACHILLION PHARMACEUTICALS, INC.
STREET 2: 300 GEORGE STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06511
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Intra-Cellular Therapies, Inc.
CENTRAL INDEX KEY: 0001567514
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 364742850
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 430 EAST 29TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10016
BUSINESS PHONE: 212-923-3344
MAIL ADDRESS:
STREET 1: 430 EAST 29TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10016
FORMER COMPANY:
FORMER CONFORMED NAME: Oneida Resources Corp.
DATE OF NAME CHANGE: 20130122
4
1
ownership.xml
4
X0508
4
2024-06-18
0001567514
Intra-Cellular Therapies, Inc.
ITCI
0001225198
VAN NOSTRAND ROBERT L
C/O INTRA-CELLULAR THERAPIES, INC.
430 EAST 29TH STREET
NEW YORK
NY
10016
true
false
false
false
true
Common Stock
2024-06-18
4
M
false
20000
16.86
A
29690
D
Common Stock
2024-06-18
4
S
false
8891
75.71
D
20799
D
Common Stock
2024-06-18
4
S
false
11109
76.07
D
9690
D
Stock Option (right to buy)
16.86
2024-06-18
4
M
false
20000
0.00
D
2024-06-30
Common Stock
20000
0
D
On June 18, 2024, the reporting person exercised options to purchase 20,000 shares of common stock that are expiring on June 30, 2024.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2024.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.01 to $76.00, inclusive. The reporting person undertakes to provide to the Issuer, any secuirty holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.01 to $76.09, inclusive. The reporting person undertakes to provide to the Issuer, any secuirty holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
This option was granted on June 30, 2014 and will expire on June 30, 2024. All shares underlying this option have vested.
/s/ Lawrence J. Hineline, Attorney-in-fact
2024-06-21